HOOK Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2024-04-15 | Orlinger Klaus | officer: Chief Scientific Officer | 367,300 | A-Award | A | 367,300 | 0.76 | 279,148.00 |
| 2024-04-15 | Aldag Jorn | director, officer: Chief Executive Officer | 971,400 | A-Award | A | 971,400 | 0.76 | 738,264.00 |
| 2024-04-15 | Winderlich Mark | officer: Chief Development Officer | 250,000 | A-Award | A | 250,000 | 0.76 | 190,000.00 |
| 2024-04-15 | Winderlich Mark | officer: Chief Development Officer | 50,000 | A-Award | A | 50,000 | 0.76 | 38,000.00 |
| 2024-04-15 | Kandera Reinhard | director, officer: Chief Financial Officer | 406,200 | A-Award | A | 406,200 | 0.76 | 308,712.00 |
| 2024-04-15 | Necina Roman | officer: Chief Operations Officer | 367,300 | A-Award | A | 367,300 | 0.76 | 279,148.00 |
| 2024-04-01 | Winderlich Mark | 0 | 0 | 0.00 | 0.00 | |||
| 2023-12-20 | GILEAD SCIENCES, INC. | 10 percent owner | 18,759,465 | D | 0 | 0.00 | 0.00 | |
| 2023-08-21 | Kandera Reinhard | director, officer: Chief Financial Officer | 43,092 | P-Purchase | A | 7,000 | 0.73 | 5,075.00 |
| 2023-08-16 | Kandera Reinhard | director, officer: Chief Financial Officer | 36,092 | P-Purchase | A | 8,000 | 0.71 | 5,712.00 |
| 2023-07-11 | Aldag Jorn | director, officer: Chief Executive Officer | 71,952 | P-Purchase | A | 5,000 | 0.83 | 4,142.00 |
| 2023-07-07 | Aldag Jorn | director, officer: Chief Executive Officer | 66,952 | P-Purchase | A | 5,000 | 0.81 | 4,050.00 |
| 2023-07-05 | Aldag Jorn | director, officer: Chief Executive Officer | 61,952 | P-Purchase | A | 5,000 | 0.89 | 4,450.00 |
| 2023-07-03 | Aldag Jorn | director, officer: Chief Executive Officer | 56,952 | P-Purchase | A | 5,000 | 0.89 | 4,456.00 |
| 2023-06-30 | Kandera Reinhard | director, officer: Chief Financial Officer | 28,092 | P-Purchase | A | 12,000 | 0.88 | 10,560.00 |
| 2023-06-09 | Peters Malte | director | 52,000 | A-Award | A | 52,000 | 1.01 | 52,520.00 |
| 2023-06-09 | Reilly Timothy P. | director | 26,000 | A-Award | A | 26,000 | 1.01 | 26,260.00 |
| 2023-06-09 | O'Neill Julie | director | 26,000 | A-Award | A | 26,000 | 1.01 | 26,260.00 |
| 2023-06-09 | van de Winkel Jan | director | 52,000 | A-Award | A | 52,000 | 1.01 | 52,520.00 |
| 2023-06-09 | Kaufman David Ross | director | 26,000 | A-Award | A | 26,000 | 1.01 | 26,260.00 |
| 2023-06-09 | Coelho Mary Theresa | director | 52,000 | A-Award | A | 52,000 | 1.01 | 52,520.00 |
| 2023-04-14 | Orlinger Klaus | officer: Chief Scientific Officer | 194,200 | A-Award | A | 194,200 | 1.00 | 194,200.00 |
| 2023-04-14 | Necina Roman | officer: Chief Development Officer | 112,100 | A-Award | A | 112,100 | 1.00 | 112,100.00 |
| 2023-04-14 | Schlienger Katia | officer: Chief Medical Officer | 184,000 | A-Award | A | 184,000 | 1.00 | 184,000.00 |
| 2023-04-14 | Baker Christine D. | officer: Chief Operating Officer | 275,800 | A-Award | A | 275,800 | 1.00 | 275,800.00 |
| 2023-04-14 | Kandera Reinhard | director, officer: Chief Financial Officer | 214,800 | A-Award | A | 214,800 | 1.00 | 214,800.00 |
| 2023-04-14 | Aldag Jorn | director, officer: Chief Executive Officer | 513,600 | A-Award | A | 513,600 | 1.00 | 513,600.00 |
| 2023-03-09 | Schlienger Katia | officer: Chief Medical Officer | 1,300 | I | 0 | 0.00 | 0.00 | |
| 2023-03-09 | Schlienger Katia | officer: Chief Medical Officer | 0 | D | 27,952 | 12.00 | 335,424.00 | |
| 2023-03-09 | Schlienger Katia | officer: Chief Medical Officer | 0 | D | 17,760 | 1.66 | 29,482.00 | |
| 2023-01-01 | Peters Malte | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2023-04-03 | Coelho Mary Theresa | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2022-06-30 | van de Winkel Jan | director: | 40,000 | A-Award | A | 40,000 | 0.00 | 0.00 |
| 2022-06-30 | van de Winkel Jan | director | 40,000 | A-Award | A | 40,000 | 1.63 | 65,200.00 |
| 2022-06-30 | Reilly Timothy P. | director: | 40,000 | A-Award | A | 40,000 | 0.00 | 0.00 |
| 2022-06-30 | Orlinger Klaus | officer: Chief Scientific Officer | 48,350 | A-Award | A | 48,350 | 0.00 | 0.00 |
| 2022-06-30 | Orlinger Klaus | officer: Chief Scientific Officer | 48,350 | A-Award | A | 48,350 | 1.66 | 80,261.00 |
| 2022-06-30 | O'Neill Julie | director: | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2022-06-30 | Necina Roman | officer: Chief Technology Officer | 48,350 | A-Award | A | 48,350 | 0.00 | 0.00 |
| 2022-06-30 | Necina Roman | officer: Chief Technology Officer | 48,350 | A-Award | A | 48,350 | 1.66 | 80,261.00 |
| 2022-06-30 | Matushansky Igor | officer: Chief Medical Officer | 92,950 | A-Award | A | 92,950 | 0.00 | 0.00 |
| 2022-06-30 | Kelly Michael Aaron | director: | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2022-06-30 | Kaufman David Ross | director: | 20,000 | A-Award | A | 20,000 | 0.00 | 0.00 |
| 2022-06-30 | Kandera Reinhard | officer: Chief Financial Officer | 92,950 | A-Award | A | 92,950 | 0.00 | 0.00 |
| 2022-06-30 | Kandera Reinhard | director, officer: Chief Financial Officer | 92,950 | A-Award | A | 92,950 | 1.66 | 154,297.00 |
| 2022-06-30 | Baker Christine D. | officer: Chief Operating Officer | 100,000 | A-Award | A | 100,000 | 0.00 | 0.00 |
| 2022-06-30 | Aldag Jorn | officer: Chief Executive Officer | 275,250 | A-Award | A | 275,250 | 0.00 | 0.00 |
| 2022-06-30 | Aldag Jorn | director, officer: Chief Executive Officer | 275,250 | A-Award | A | 275,250 | 1.66 | 456,915.00 |
| 2022-04-19 | Orlinger Klaus | officer: Chief Scientific Officer | 48,350 | A-Award | A | 48,350 | 0.00 | 0.00 |
| 2022-04-19 | Orlinger Klaus | officer: Chief Scientific Officer | 48,350 | A-Award | A | 48,350 | 1.66 | 80,261.00 |
| 2022-04-19 | Necina Roman | officer: Chief Technology Officer | 48,350 | A-Award | A | 48,350 | 1.66 | 80,261.00 |
| 2022-04-19 | Necina Roman | officer: Chief Technology Officer | 48,350 | A-Award | A | 48,350 | 0.00 | 0.00 |
| 2022-04-19 | Matushansky Igor | officer: Chief Medical Officer | 92,950 | A-Award | A | 92,950 | 0.00 | 0.00 |
| 2022-04-19 | Kandera Reinhard | officer: Chief Financial Officer | 92,950 | A-Award | A | 92,950 | 0.00 | 0.00 |
| 2022-04-19 | Kandera Reinhard | director, officer: Chief Financial Officer | 92,950 | A-Award | A | 92,950 | 1.66 | 154,297.00 |
| 2022-04-19 | Baker Christine D. | officer: Chief Business Officer | 100,000 | A-Award | A | 100,000 | 0.00 | 0.00 |
| 2022-04-19 | Aldag Jorn | director, officer: Chief Executive Officer | 275,250 | A-Award | A | 275,250 | 1.66 | 456,915.00 |
| 2022-04-19 | Aldag Jorn | officer: Chief Executive Officer | 275,250 | A-Award | A | 275,250 | 0.00 | 0.00 |
| 2022-04-15 | Reilly Timothy P. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2022-02-15 | GILEAD SCIENCES INC | 10 percent owner | 3,759,465 | D | 0 | 0.00 | 0.00 | |
| 2022-02-01 | Orlinger Klaus | officer: Executive VP, Research | 12,654 | A-Award | A | 12,654 | 1.50 | 18,981.00 |
| 2022-02-01 | Orlinger Klaus | officer: Executive VP, Research | 10,404 | A-Award | A | 9,188 | 3.00 | 27,564.00 |
| 2022-02-01 | Baker Christine D. | officer: Chief Business Officer | 22,763 | A-Award | A | 22,763 | 1.50 | 34,144.00 |
| 2022-02-01 | Baker Christine D. | officer: Chief Business Officer | 16,158 | A-Award | A | 13,658 | 3.00 | 40,974.00 |
| 2022-02-01 | Necina Roman | officer: Chief Technology Officer | 21,486 | A-Award | A | 21,486 | 1.50 | 32,229.00 |
| 2022-02-01 | Necina Roman | officer: Chief Technology Officer | 14,876 | A-Award | A | 12,892 | 3.00 | 38,676.00 |
| 2022-02-01 | Matushansky Igor | officer: Chief Medical Officer | 100,240 | A-Award | A | 14,933 | 3.00 | 44,799.00 |
| 2022-02-01 | Matushansky Igor | officer: Chief Medical Officer | 24,888 | A-Award | A | 24,888 | 1.50 | 37,332.00 |
| 2022-02-01 | Kandera Reinhard | director, officer: Chief Financial Officer | 23,427 | A-Award | A | 23,427 | 1.50 | 35,140.00 |
| 2022-02-01 | Kandera Reinhard | director, officer: Chief Financial Officer | 16,092 | A-Award | A | 14,056 | 3.00 | 42,168.00 |
| 2022-02-01 | Aldag Jorn | director, officer: Chief Executive Officer | 51,952 | A-Award | A | 47,824 | 3.00 | 143,472.00 |
| 2022-02-01 | Aldag Jorn | director, officer: Chief Executive Officer | 39,853 | A-Award | A | 39,853 | 1.50 | 59,780.00 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 91,544 | M-Exempt | A | 11,366 | 0.10 | 1,137.00 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 87,512 | M-Exempt | A | 3,408 | 0.10 | 340.80 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 85,482 | M-Exempt | A | 8,079 | 0.10 | 807.90 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 85,307 | S-Sale | D | 2,205 | 2.49 | 5,490.00 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 84,104 | S-Sale | D | 7,440 | 2.49 | 18,526.00 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 80,178 | S-Sale | D | 5,304 | 2.49 | 13,207.00 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 4,261 | M-Exempt | D | 3,408 | 0.10 | 340.80 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 2,842 | M-Exempt | D | 11,366 | 0.10 | 1,137.00 |
| 2021-12-21 | Matushansky Igor | officer: Chief Medical Officer | 0 | M-Exempt | D | 8,079 | 0.10 | 807.90 |
| 2021-06-01 | Seghezzi Graziano | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2021-06-01 | van de Winkel Jan | director | 19,200 | A-Award | A | 19,200 | 16.61 | 318,912.00 |
| 2021-06-01 | Soria Jean-Charles | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | Seghezzi Graziano | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | O'Neill Julie | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | Lengauer Christoph | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | Kelly Michael Aaron | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-06-01 | Kaufman David Ross | director | 9,600 | A-Award | A | 9,600 | 16.61 | 159,456.00 |
| 2021-04-21 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,177,574 | S-Sale | D | 328,620 | 11.60 | 3,812,386.00 |
| 2021-04-19 | Necina Roman | officer: Chief Technology Officer | 36,750 | A-Award | A | 36,750 | 12.00 | 441,000.00 |
| 2021-04-19 | Orlinger Klaus | officer: Sr. VP, Research | 26,050 | A-Award | A | 26,050 | 12.00 | 312,600.00 |
| 2021-04-19 | Baker Christine D. | officer: Chief Business Officer | 49,950 | A-Award | A | 49,950 | 12.00 | 599,400.00 |
| 2021-04-19 | Matushansky Igor | officer: Chief Medical Officer | 95,250 | A-Award | A | 95,250 | 12.00 | 1,143,000.00 |
| 2021-04-19 | Kandera Reinhard | officer: Chief Financial Officer | 69,300 | A-Award | A | 69,300 | 12.00 | 831,600.00 |
| 2021-04-19 | Aldag Jorn | director, officer: Chief Executive Officer | 207,600 | A-Award | A | 207,600 | 12.00 | 2,491,200.00 |
| 2021-03-29 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,506,194 | S-Sale | D | 36,829 | 13.67 | 503,570.00 |
| 2021-03-26 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,543,023 | S-Sale | D | 35,171 | 13.69 | 481,642.00 |
| 2021-03-25 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,578,194 | S-Sale | D | 28,546 | 13.12 | 374,569.00 |
| 2021-03-24 | SOFINNOVA CAPITAL VI FCPR | 10 percent owner | 3,606,740 | S-Sale | D | 52,690 | 13.70 | 721,616.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
